|
US2019127461A1
|
|
Cancer treatment pharmaceutical composition using anti-mct5 antibody
|
|
JP2018158894A
|
|
Monoclonal antibodies
|
|
CN108699141A
|
|
High-affinity anti-vegf antibody
|
|
US2019322732A1
|
|
Antibody inhibiting binding of vegf to nrp1
|
|
WO2016052756A1
|
|
Reagent for detecting or diagnosing cancer cells having high invasive capacity
|
|
WO2015152417A1
|
|
Method for producing antibody against target antigen
|
|
WO2015129919A1
|
|
Anti-slc6a6 antibody and pharmaceutical composition for cancer treatment including said antibody
|
|
EP3095462A1
|
|
Therapeutic pharmaceutical composition employing anti-slc6a6 antibody
|
|
CA2913924A1
|
|
Reagent including anti-lgr6 antibodies for detection and diagnosis of cancer
|
|
CA2866252A1
|
|
Pharmaceutical composition for treating cancer
|
|
EP2444484A1
|
|
Method for producing antibodies using cancer cells
|
